Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Determination of Renal Drug Clearance: Graphical and Midpoint Methods01:07

Determination of Renal Drug Clearance: Graphical and Midpoint Methods

Renal clearance, a crucial parameter in pharmacokinetics, can be determined using two different methods: the graphical method and the midpoint method. These methods provide insights into the rate of drug excretion by the kidneys and aid in assessing renal function.
The graphical method involves plotting the rate of drug excretion in urine against the plasma drug concentration. By analyzing the graph, the clearance can be calculated and obtained. Drugs rapidly excreted by the kidneys exhibit a...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Dosage Interval and Administration Route: Determination Methods01:19

Dosage Interval and Administration Route: Determination Methods

A medication’s effectiveness largely depends on its appropriate dosage and the route of administration. Dosage ensures that a sufficient drug concentration is maintained in the bloodstream to elicit the desired therapeutic effect without causing toxicity. The route of administration affects the drug's bioavailability, rate of absorption, and onset of action, which are crucial for achieving optimal therapeutic outcomes. Drug dosage calculations are critical to tailoring therapy to individual...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An examination of the availability and characteristics of social needs data in the electronic health records: a path to social data harmonization and standardization at Johns Hopkins medicine.

JAMIA open·2026
Same author

Neuroretinal Layer Thinning on OCT Imaging and Hemoglobin A1c in Youth With Type 1 Diabetes.

JAMA ophthalmology·2026
Same author

Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study.

Ophthalmology·2026
Same author

Beyond Missingness: Systematizing Methods for Comprehensive Data Fitness Assessment in Clinical Research.

Journal of medical Internet research·2026
Same author

The Potential Implications of Informatics for Value-Based Bare.

Journal of the American Medical Informatics Association : JAMIA·2026
Same author

PyOPV: An Open-Source Python Package for Ophthalmic Visual Field Data Management.

Journal of glaucoma·2026

Related Experiment Video

Updated: Jun 14, 2026

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level
05:35

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

Published on: January 19, 2024

A new method for determining physician decision thresholds using empiric, uncertain recommendations.

Michael V Boland1, Harold P Lehmann

  • 1Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA. boland@jhu.edu

BMC Medical Informatics and Decision Making
|April 10, 2010
PubMed
Summary
This summary is machine-generated.

A new method estimates physician treatment thresholds for ocular hypertension without requiring explicit risk probability assessments. This approach better models clinical decision-making and aids in evaluating interventions.

Related Experiment Videos

Last Updated: Jun 14, 2026

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level
05:35

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

Published on: January 19, 2024

Area of Science:

  • Medical Decision Making
  • Ophthalmology
  • Health Services Research

Background:

  • Physician risk threshold estimation is crucial in medical decision-making but historically challenging.
  • Physicians often struggle with accurately estimating patient risk probabilities.
  • Ocular hypertension management is evolving with new risk factors identified in recent clinical research.

Purpose of the Study:

  • To develop and test a novel method for assessing physician treatment thresholds.
  • To model medical decision-making more accurately by deriving thresholds from treatment recommendations.
  • To evaluate how ophthalmologists incorporate new risk factors into treatment decisions for ocular hypertension.

Main Methods:

  • Developed an ordinal logistic regression model to estimate treatment thresholds.
  • Recruited 58 ophthalmologists from the American Glaucoma Society.
  • Physicians reviewed ocular hypertension cases and indicated likelihood of recommending treatment.

Main Results:

  • Estimated individual physician treatment thresholds, revealing wide variation.
  • Validated the method by showing common thresholds aligned with expert-recommended 10-15% 5-year glaucoma risk.
  • Demonstrated the method's consistency with established decision analysis findings.

Conclusions:

  • The new method avoids direct physician risk probability estimation.
  • It accommodates uncertainty in clinical recommendations.
  • This approach is valuable for assessing interventions aimed at modifying physician decision-making processes.